We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+32.76%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.72B
AUM Growth
+$1.24B
Cap. Flow
+$495M
Cap. Flow %
8.66%
Top 10 Hldgs %
39.54%
Holding
129
New
28
Increased
37
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$84.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$65.7M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$65.1M
5
PCVX icon
Vaxcyte
PCVX
+$58.5M

Top Sells

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$257M
2
CBAY
Cymabay Therapeutics
CBAY
+$95.1M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.3M
4
ACLX
Arcellx
ACLX
+$38.8M
5
ABBV icon
AbbVie
ABBV
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
101
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.95M 0.05%
+600,000
New +$3.55M
AGIO icon
102
CALL
Agios Pharmaceuticals
AGIO
$2.11B
$2.92M 0.05%
+100,000
New +$2.68M
FBRX icon
103
Forte Biosciences
FBRX
$1.57B
$2.27M 0.04%
130,614
– –
OMIC
104
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.09M 0.02%
70,896
– –
KURA icon
105
Kura Oncology
KURA
$818M
$1.03M 0.02%
+48,200
New +$937K
AMLX icon
106
Amylyx Pharmaceuticals
AMLX
$2.22B
$852K 0.01%
300,000
-1,569,125
-84% -$20.5M
VBIV
107
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$757K 0.01%
1,261,710
-119,645
-9% -$73.3K
SYRS
108
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$625K 0.01%
+116,754
New +$807K
CMAX
109
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$591K 0.01%
122,643
– –
RVMDW icon
110
Revolution Medicines Inc Warrant
RVMDW
$96.8M
$45.6K ﹤0.01%
250,000
– –
SRZNW icon
111
Surrozen Inc Warrant
SRZNW
$36.6K
$5.03K ﹤0.01%
166,666
– –
CMAXW
112
DELISTED
CareMax, Inc. Warrant
CMAXW
$1.03K ﹤0.01%
60,000
– –
ACAD icon
113
Acadia Pharmaceuticals
ACAD
$4.53B
– –
-101,000
Closed -$3.16M
ASND icon
114
Ascendis Pharma A/S
ASND
$16.6B
– –
-132,176
Closed -$16.6M
BCAB icon
115
BioAtla
BCAB
$5.36M
– –
-1,460
Closed -$180K
CYTK icon
116
Cytokinetics
CYTK
$10.8B
– –
-30,317
Closed -$2.53M
EYPT icon
117
PUT
EyePoint Inc
EYPT
$1.01B
– –
-750,000
Closed -$37.5K
KRON
118
DELISTED
Kronos Bio
KRON
– –
-1,752,745
Closed -$2.19M
CYPH
119
Cypherpunk Technologies Inc
CYPH
$64.9M
– –
-44,971
Closed -$186K
MIRM icon
120
Mirum Pharmaceuticals
MIRM
$6.69B
– –
-534,942
Closed -$15.8M
OLMA icon
121
Olema Pharmaceuticals
OLMA
$998M
– –
-539,831
Closed -$7.57M
RGNX icon
122
Regenxbio
RGNX
$628M
– –
-342,408
Closed -$6.15M
TERN
123
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,075,000
Closed -$6.98M
TNGX icon
124
Tango Therapeutics
TNGX
$4.27B
– –
-1,111,870
Closed -$11M
TVTX icon
125
Travere Therapeutics
TVTX
$5.29B
– –
-400,000
Closed -$3.6M
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Perceptive Advisors held 129 positions worth $5.72B, up 28% from $4.48B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Perceptive Advisors deployed $495M of net new capital in Q1 2024, opening 28 new positions and adding to 37 existing holdings. Its largest new stake was CG Oncology: 1,304,105 shares worth $57.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $38.8M trimmed.

  • Perceptive Advisors's largest Q1 2024 buy was CG Oncology: 1,304,105 shares worth $57.3M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2024, an estimated $84.9M increase.
  • Perceptive Advisors's biggest Q1 2024 reduction was Arcellx, cutting an estimated $38.8M.
  • Perceptive Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $257M.
  • Perceptive Advisors's ten largest holdings make up 40% of its $5.72B portfolio in Q1 2024.
  • Perceptive Advisors opened 28 new positions and closed 17 in Q1 2024.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $5.72B.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.